Onderneming Suda Pharmaceuticals Ltd Australian S.E.
Aandelen
SUD
AU0000063661
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- AUD | -.--% | -.--% | -.--% |
Vakgebied
Verkoop per activiteit
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical Development
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +37,22% |
Verkoop per regio
AUD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Australia
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +37,22% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 02-01-20 |
Tim Luscombe
DFI | Director of Finance/CFO | - | 01/12 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Chief Operating Officer | - | 04-01-23 | |
Mini Bharathan
PRN | Corporate Officer/Principal | - | 01-02-22 |
Deborah Cooper
PRN | Corporate Officer/Principal | - | - |
Phillip Hains
SEC | Corporate Secretary | 64 | 01-07-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 01-07-22 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 10-11-21 |
Thomas Duthy
CHM | Chairman | - | 13-03-23 |
Michael Baker
CEO | Chief Executive Officer | - | 02-01-20 |
Debora Barton
BRD | Director/Board Member | 48 | 10-08-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 909 628 062 | 831 895 931 ( 91,45 %) | 0 | 91,45 % |
Bedrijfsgegevens
Arovella Therapeutics Ltd.
62 Lygon Street Level 3, Suite 1
3053, Carlton South
+61 3 9863 6472
http://www.arovella.comSector
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,37% | 46,71 mld. | |
+48,83% | 41,8 mld. | |
-0,94% | 41,52 mld. | |
-5,86% | 29,55 mld. | |
+11,29% | 25,78 mld. | |
-20,92% | 19,26 mld. | |
+3,20% | 12,14 mld. | |
-2,67% | 12,08 mld. | |
+30,23% | 11,98 mld. |